

Amendments to the Specification

Please replace the paragraph at page 13, lines 16 through 20 with the following amended paragraph:

Another aspect of the invention concerns methods for lowering the concentration of bile acids in a mammal, comprising the use of an FXR agonist in a pharmacologically acceptable carrier. Alternatively, in another aspect of the invention an FXR antagonist or FXR ~~reverse~~ inverse agonist is used to increase the synthesis of bile acids in a patient deficient in bile acid synthesis.